Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Hosted on MSN2d
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last WeekAIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...
Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.
Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...
This innovative approach works by NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
Marketing guru Tiziana Rocca, who has close Hollywood ties and is a festivals specialist, has been appointed artistic director of Italy’s Taormina Film Festival in a move that brings her back at ...
Tiziana Life Sciences, Ltd. has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback